A retrospective study of more than 18,000 real-world patients found that those on tirzepatide were more than three times as likely to hit 15% weight loss within a year compared with those on semaglutide
Granhall C, Donsmark M, Blicher TM, Golor G, Sndergaard FL, Thomsen M, et al
Tirzepatide Next-generation dual-receptor therapy Activates both GLP-1 and GIP receptors delivering superior appetite control and stronger metabolic outcomes than single-pathway medications
What happens to the dose schedule if I experience severe nausea
The current label for Ozempic, for instance, mentions the risk of diabetic retinopathy complications, particularly in patients with a history of diabetic retinopathy
Sikirica M, Martin A, Wood R, Leith A, Piercy J, Higgins V